• MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro 

      Svartdal, Lisa Gregusson; Aure, Miriam Ragle; Leivonen, Suvi-Katri; Haugen, Mads Haugland; Hongisto, Vesa; Kristensen, Vessela N.; Mælandsmo, Gunhild Mari; Sahlberg, Kristine Kleivi (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-05-25)
      HER2-positive (HER2 +) breast cancer patients that do not respond to targeted treatment have a poor prognosis. The effects of targeted treatment on endogenous microRNA (miRNA) expression levels are unclear. We report that responsive HER2 + breast cancer cell lines had a higher number of miRNAs with altered expression after treatment with trastuzumab and lapatinib compared to poorly responsive cell ...